ARWR — Arrowhead Pharmaceuticals, Inc. stock price, charts and financials
QT66Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -2.14 | Insider Own | 5.49% | Shs Outstand | 140.86M | Perf Week | 4.44% |
| Market Cap | 12.62B | Forward P/E | - | EPS next Y | -4.41 | Insider Trans | -0.47% | Shs Float | 122.78M | Perf Month | 3.51% |
| Enterprise Value | 12.21B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.85% | Perf Quarter | 17.28% |
| Income | -301.00M | P/S | 20.29 | EPS this Y | -47.62% | Inst Trans | - | Short Ratio | 4.59 | Perf Half Y | 22.73% |
| Sales | 622.00M | P/B | 21.07 | EPS next Y | -39.71% | ROA | -13.27% | Short Interest | 9.64M | Perf YTD | 34.95% |
| Book/sh | 4.25 | P/C | 7.07 | EPS next 5Y | - | ROE | -55.45% | 52W High | 95.49 -6.18% | Perf Year | 462.40% |
| Cash/sh | 12.67 | P/FCF | - | EPS past 3/5Y | - | ROIC | -10.98% | 52W Low | 15.01 496.87% | Perf 3Y | 155.02% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 50.54% 56.61% | Gross Margin | - | Volatility | 3.92% 4.84% | Perf 5Y | 35.85% |
| Dividend TTM | - | EV/Sales | 19.63 | EPS Y/Y TTM | 57.20% | Oper. Margin | -35.67% | ATR (14) | 4.29 | Perf 10Y | 1485.66% |
| Dividend Ex-Date | - | Quick Ratio | 6.23 | Sales Y/Y TTM | 15450.00% | Profit Margin | -48.38% | RSI (14) | 63.10 | Recom | 2.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.23 | EPS Q/Q | 115.83% | SMA20 | 10.47% | Beta | 1.26 | Target Price | 103.33 |
| Payout | 0.00% | Debt/Eq | 0.71 | Sales Q/Q | -86.37% | SMA50 | 13.07% | Rel Volume | 0.92 | Prev Close | 86.01 |
| Employees | 711 | LT Debt/Eq | 0.63 | Earnings | Nov 24 | SMA200 | 36.37% | Avg Volume | 2.22M | Price | 89.59 |
| IPO Date | Dec 16, 1993 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 491.83% 23.41% | Net Debt/EBITDA | -8.81 | Volume | 2,030,880 | Change | 4.16% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-27-26 | Reiterated | HC Wainwright & Co. | Buy | $100 → $115 |
| Jul-23-26 | Reiterated | Piper Sandler | Overweight | $110 → $126 |
| Jul-23-26 | Reiterated | Morgan Stanley | Overweight | $100 → $120 |
| Jul-22-26 | Reiterated | Chardan Capital | Buy | $90 → $115 |
| Jul-13-26 | Initiated | Stifel | Buy | $98 |
| May-13-26 | Reiterated | Bernstein | Market Perform | $35 → $46 |
| May-08-26 | Reiterated | Chardan Capital | Buy | $80 → $90 |
| Apr-21-26 | Upgrade | Morgan Stanley | Equal Weight → Overweight | $78 → $100 |
| Feb-06-26 | Reiterated | Morgan Stanley | Equal Weight | $81 → $78 |
| Jan-27-26 | Reiterated | Robert W. Baird | $81 |
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 622 | 829 | 4 | 241 | 243 | 138 | 88 | 169 | 16 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 19 | 12 | 10 | 0 | 0 | 0 | 0 | |
| Gross Profit | 622 | 829 | -15 | 228 | 233 | 138 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 154 | 122 | 97 | 91 | 124 | 81 | 52 | 27 | 19 | |
| Research and Development | 687 | 607 | 489 | 342 | 289 | 199 | 124 | 77 | 48 | |
| Other Operating Expense | 2 | 2 | 0 | 0 | -2 | -1 | -1 | -1 | 0 | |
| Operating Income | -222 | 98 | -601 | -205 | -179 | -149 | -93 | 61 | -56 | |
| Interest Expense | 93 | 89 | 32 | 18 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 63 | 43 | 21 | 17 | 6 | 8 | 9 | 7 | 1 | |
| Net Income Before Taxes | -253 | 52 | -612 | -206 | -173 | -141 | -85 | 68 | -54 | |
| Income Taxes | 20 | 21 | -3 | 3 | 4 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -301 | -2 | -599 | -205 | -176 | -141 | -85 | 68 | -54 | |
| Net Income From Continuing Operations | -273 | 30 | -610 | -209 | -176 | -141 | -85 | 68 | -54 | |
| Net Income | -301 | -2 | -599 | -205 | -176 | -141 | -85 | 68 | -54 | |
| EPS (Recurring) | -2.14 | -0.01 | -5.00 | -1.91 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | |
| EPS (Basic, Before Extraordinaries) | -2.14 | -0.01 | -5.00 | -1.91 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | |
| EPS (Diluted) | -2.14 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | -0.65 | |
| EBITDA | -134 | 165 | -562 | -176 | -162 | -133 | -87 | 66 | -51 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | 40.84 | — | |
| Price To Sales Ratio | 20.45 | 5.57 | 581.10 | 11.93 | 14.28 | 47.05 | 49.42 | 15.67 | 100.64 | |
| Gross Margin | 100.00 | 100.00 | -375.00 | 94.61 | 95.88 | 100.00 | 0.00 | 0.00 | 0.00 | |
| Operating Margin | -35.69 | 11.82 | -15,025.00 | -85.06 | -73.66 | -107.97 | -105.68 | 36.09 | -350.00 | |
| Net Margin | -48.39 | -0.24 | -14,975.00 | -85.06 | -72.43 | -102.17 | -96.59 | 40.24 | -337.50 | |
| Shares Outstanding | 142 | 134 | 120 | 107 | 105 | 104 | 101 | 94 | 84 | |
| Market Capitalization | 12,722 | 4,622 | 2,324 | 2,875 | 3,470 | 6,493 | 4,349 | 2,649 | 1,610 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lu Hongbo | Director | May 12 '26 | Sale | 76.88 | 2,970 | 228,334 | 52,012 | May 14 |
| Hamilton James C | Chief Medical Officer | Apr 23 '26 | Sale | 75.00 | 10,000 | 750,000 | 226,958 | Apr 24 |
| Apel Daniel Joseph | Chief Financial Officer | Apr 22 '26 | Sale | 71.35 | 13,095 | 934,286 | 162,905 | Apr 24 |
| Hamilton James C | Chief Medical Officer | Mar 05 '26 | Sale | 64.19 | 10,000 | 641,900 | 236,958 | Mar 09 |
| Hamilton James C | Chief Medical Officer | Jan 05 '26 | Sale | 63.11 | 40,164 | 2,534,661 | 171,958 | Jan 05 |
| O'Brien Patrick | COO | Jan 05 '26 | Sale | 63.11 | 49,493 | 3,123,349 | 474,908 | Jan 05 |
| Anzalone Christopher Richard | Chief Executive Officer | Jan 02 '26 | Sale | 66.10 | 13,187 | 871,703 | 3,792,739 | Jan 05 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 29 '25 | Option Exercise | 6.15 | 51,726 | 318,115 | 3,857,652 | Dec 30 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 29 '25 | Sale | 69.13 | 51,726 | 3,575,575 | 3,805,926 | Dec 30 |
| Ferrari Mauro | Director | Dec 26 '25 | Sale | 70.00 | 7,530 | 527,100 | 69,053 | Dec 30 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 22 '25 | Sale | 68.44 | 12,586 | 861,340 | 3,805,926 | Dec 23 |
| OLUKOTUN ADEOYE Y | Director | Dec 19 '25 | Sale | 67.66 | 10,000 | 676,623 | 33,600 | Dec 23 |
| Waddill William D. | Director | Dec 19 '25 | Sale | 67.65 | 8,367 | 566,039 | 56,563 | Dec 23 |
| Vakiener Victoria | Director | Dec 19 '25 | Sale | 67.68 | 10,040 | 679,491 | 35,723 | Dec 23 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 19 '25 | Sale | 67.66 | 13,445 | 909,682 | 3,818,512 | Dec 23 |